Toggle navigation
The UK Cystic Fibrosis Gene Therapy Consortium
News
About Us
About
About
About
Who are we
Consortium Timeline
Profiles of the Consortium Strategy Group
Frequently Asked Questions
All Trials Registered Initiative
Contact Details
About this Website
Mailform
Videos
Funding
Funding
Funding
Funding
Funding Overview
Flutterby FUNdraisers
The Cystic Fibrosis Trust
Just Gene Therapy
Cystic Fibrosis
CF
CF
CF
What is Cystic Fibrosis?
History of Cystic Fibrosis
Discovery of the CFTR Gene
What causes Cystic Fibrosis?
CFTR Protein Structure
Gene Therapy
Introduction to Gene Therapy
Why use Gene Therapy to Treat CF?
Other CF Gene Therapy Groups
Successful Applications of Gene Therapy
CF Gene Therapy Clinical Trials
Clinical Programme
Clinical
Clinical
Clinical
GL67A pGM169 - Our first clinical trial product
The Tracking Study
The Run In Study
Single Dose Clinical Trial (2009-2011)
Multi Dose Clinical Trial (2012-2014)
Multi Dose Clinical Trial Protocol
Public Meeting, 30 May 2015
Research
Nonviral Vector Development
Aerosol Delivery of Gene Transfer Vectors
Assay Development
Lentiviral Vector Development
Lentiviral Production
Publications
Journal Articles
Conference Presentations
Book Chapters
Public Presentations
Blog
Journal Articles
Conference Presentations
Book Chapters
Public Presentations
Papers 1
Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.
Lund-Palau H et al., Expert Rev Respir Med. 2016 Jun;10(6):685-97. doi: 10.1080/17476348.2016.1177460. Epub 2016 May 13.
Lentivirus Animation (2011): Basic description of Lentivirus Pseudotyping.
More...
A frozen vial of GL67A (left) and a frozen vial of pGM169 plasmid DNA (right)